The multi-analyte Zika virus assay was developed by a Luminex partner, GenArraytion, and is available now for research use only.
The company attributed the increase predominantly to a continued adoption of its infectious disease menu by US microbiology laboratories.
The platform and the assay were cleared by the US Food and Drug Administration in October and were launched in the US shortly thereafter.
The company's full-year revenues rose 5 percent, with revenue from assay sales increasing 15 percent for the year and 12 percent for the quarter.
The exchange warned the company that its stock could be delisted if it doesn't meet the $1.00 minimum required closing bid price.
Executives from Luminex, Exact Sciences, T2 Biosystems, and Singulex provided updates on their companies' businesses on the final day of the conference.
The molecular diagnostics company also reported 35 new customer placements in the fourth quarter.
Agilent will pay Enzo $9 million to settle the suit, which involved a US patent issued to Enzo and describing non-porous solid supports for nucleic acids.
The firm priced each share at $.47, and plans to use the funding for general corporate purposes and working capital.
With this clearance, the respiratory pathogen panel is ready to enter the market to aid in accurate patient diagnosis for respiratory illness.
A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.
NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.
The New York Times reports on how environmental DNA sampling could monitor endangered species.
In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.